Table 2.
Alteration in final body weights, food intake, liver weights, and fasting plasma and levels glucose in all experimental groups.
| Parameter | Control | Control + EA | Control + EA + CC | T1DM | T2DM + EA | T1DM + EA + CC |
|---|---|---|---|---|---|---|
| Plasma | ||||||
| Final body weight (g) | 412 ± 46 | 429 ± 31 | 444 ± 29 | 339 ± 41abc | 409 ± 21d | 319 ± 29abce |
| Liver weights (g) | 15.6 ± 2.8 | 15.9 ± 2.2 | 14.3 ± 2.5 | 21.8 ± 3.1abc | 16.5 ± 2.9d | 19.9 ± 3.3abce |
| Weekly food intake (g/6 rats) | 1212 ± 100 | 1190 ± 119 | 1231 ± 87 | 1876 ± 147abc | 1321 ± 189d | 1992 ± 214abce |
| Fasting glucose (mg/dl) | 103 ± 7.8 | 86 ± 6.9a | 112 ± 6.4b | 328 ± 22.4abc | 181 ± 14.5abcd | 356 ± 33.1abce |
| Fasting insulin | 4.6 ± 0.55 | 4.1 ± 0.67 | 4.7 ± 0.71 | 1.4 ± 0.25abc | 2.7 ± 0.61abcd | 1.1 ± 0.31abce |
| Serum | ||||||
| ALT (U/l) | 41 ± 7.8 | 45 ± 8.1 | 41 ± 5.9 | 113 ± 11.7abc | 56 ± 5.7abcd | 109 ± 8.5abce |
| AST (U/l) | 23.4 ± 4.7 | 25.7 ± 6.1 | 21.5 ± 6.3 | 93.5 ± 8.4abc | 37.1 ± 6.2abcd | 93.2 ± 7.1abce |
Data are presented as the mean ± SD for n = 8 rats/group. Significance was determined at p < 0.05. a: significantly different as compared to control; b: significantly different as compared to control + Ellagic acid (EA); c: significantly different as compared to control + EA + compound C (CC, and AMKP inhibitor); d: significantly different as compared to T1DM-induced rats; and e: significantly different as compared to T1DM + EA-treated rats.